New Targeted Therapy Nearly Doubles Survival in Late-Stage Pancreatic Cancer Trials

Published: May 7, 2026

In a landmark development for oncology, Revolution Medicines announced this week that its experimental oral drug, daraxonrasib, nearly doubled the median overall survival for patients battling previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). Results from a pivotal Phase 3 clinical trial revealed that patients receiving the drug lived a median of 13.2 months, compared to just 6.7 months for those receiving standard-of-care chemotherapy.

The findings, reported in early May 2026, represent a potential watershed moment for one of the world’s most lethal malignancies. For decades, pancreatic cancer has remained stubbornly resistant to the precision medicine revolution that has transformed the treatment of lung, breast, and skin cancers. If granted regulatory approval, daraxonrasib could become the first therapy to successfully neutralize the genetic “engine” driving over 90% of pancreatic tumors.

The “Undruggable” Target: Overcoming the RAS Barrier

To understand the significance of daraxonrasib, one must look at the biology of pancreatic cancer. More than 90% of PDAC cases are driven by mutations in the RAS gene family, specifically KRAS. These mutations act like a broken “on” switch, signaling cancer cells to multiply uncontrollably.

Historically, the RAS protein was considered “undruggable” due to its smooth, ball-like structure, which offered no obvious pockets for traditional drugs to latch onto. While recent years saw the approval of inhibitors for specific subtypes (like KRAS G12C), these only applied to a tiny fraction of pancreatic patients.

Daraxonrasib employs a sophisticated “indirect” strategy. Instead of attacking the mutant RAS protein directly, the daily oral pill binds to a companion protein called SOS1. This creates a molecular complex that effectively jams the machinery RAS needs to activate, cutting off the tumor’s growth signals at the source.

Breakthrough Data: A Shift in the Survival Curve

The Phase 3 trial included 501 participants with metastatic PDAC who had already seen their cancer progress after initial rounds of chemotherapy. This is a patient population that typically faces a very poor prognosis, often measured in only a few months.

Key Clinical Outcomes:

• Median Overall Survival: 13.2 months (Daraxonrasib) vs. 6.7 months (Chemotherapy).

• Response Rates: While full peer-reviewed data is pending, early reports indicate significant tumor shrinkage in a substantial portion of the daraxonrasib group.

• Administration: The treatment is a daily oral pill, a significant shift from the grueling intravenous infusions required for chemotherapy.

“These are truly unprecedented overall survival results,” said Mark Goldsmith, CEO of Revolution Medicines, in a statement accompanying the data. “We are significantly elevating the survival bar in one of the deadliest human cancers.”

Expert Perspectives: “Practice-Changing”

The medical community has greeted the news with a mixture of excitement and professional caution. Dr. Brian Wolpin, the trial’s principal investigator, described the results as “a very important advance” that is “expected to be practice-changing for physicians.”

External experts agree. Leonid Timashev, an analyst at RBC Capital Markets who has followed the drug’s development, noted that many oncologists are describing this as “potentially the biggest breakthrough in pancreatic cancer ever.”

However, some urge a grounded perspective. Dr. Dushyant Mahalingam, an oncologist unaffiliated with the study, told TIME that while the results are “dramatic,” the drug is not yet a cure. “We are not curing patients… but patients are living longer,” he emphasized. The goal of such precision therapy is to turn a terminal diagnosis into a manageable chronic condition.

The Patient Experience: Ben Sasse’s Story

The statistical gains are perhaps best illustrated by individual patient stories. Ben Sasse, the former U.S. Senator who was diagnosed with pancreatic cancer in late 2025, participated in a separate arm of the trial.

Before starting the regimen, Sasse’s prognosis was 3 to 4 months. After treatment, he reported a 60% reduction in tumor volume and a massive drop in his CA 19-9 tumor marker (a protein used to monitor pancreatic cancer) from over 8,000 to 374. This reduction in tumor burden not only extends life but significantly reduces the debilitating pain often associated with the disease.

Safety and Quality of Life

One of the most promising aspects of daraxonrasib is its safety profile. In the Phase 3 cohort, the drug was reported to have a “high rate of mostly manageable side effects.”

• Common Side Effects: Gastrointestinal upset (nausea, diarrhea), fatigue, and skin rash.

• Comparison to Chemotherapy: Unlike traditional chemo, daraxonrasib does not typically cause hair loss or severe bone marrow suppression, which can leave patients vulnerable to life-threatening infections.

Revolution Medicines noted that no new or unexpected “safety signals” emerged during the trial, suggesting that the drug could offer a much higher quality of life for patients in their final year compared to the toxicities of standard infusions.

Public Health and the Path Forward

Pancreatic cancer remains a major public health challenge. In 2025, approximately 66,000 Americans were diagnosed with the disease, and roughly 50,000 died from it. Globally, cases are rising, fueled by aging populations and high rates of obesity and type 2 diabetes—both of which are significant risk factors.

Revolution Medicines plans to submit the drug for FDA approval using a Commissioner’s National Priority Voucher, which could expedite the review process to just one or two months. For patients who cannot wait for formal approval, the FDA has already granted “Expanded Access,” allowing doctors to request the drug for compassionate use.

Looking Ahead

The company is currently testing daraxonrasib in several other settings:

1. First-Line Therapy: Using the drug as the very first treatment a patient receives.

2. Neoadjuvant Therapy: Administering the drug before surgery to shrink tumors and make them easier to remove.

3. Other Cancers: Investigating its efficacy in lung and colorectal cancers that also harbor RAS mutations.

Limitations and Considerations

While the data is compelling, there are caveats. The current results primarily apply to patients with specific KRAS mutations. While this covers about 90% of PDAC cases, it is not a “one size fits all” solution. Furthermore, like many targeted therapies, there is a risk that the cancer will eventually develop resistance to the drug, requiring researchers to develop “second-generation” inhibitors or combination therapies.

Experts also emphasize that new treatments do not replace the need for prevention and early detection. According to the World Health Organization, lifestyle changes—such as smoking cessation, maintaining a healthy weight, and controlling diabetes—could reduce the risk of developing pancreatic cancer by 20% to 30%.

Summary of Findings

Reference Section

Study Citations & Reports:

• Reuters: “Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effects.” Published May 6, 2026.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.